Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Alper H.YUKSEL who wrote (21011)	5/18/1998 4:30:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Alper, Thanks for the heads up. I'm impressed that LGND could get a plug from a Herceptin article in the WSJ. I said that LGND would be all over ASCO, and I suspect that the media is beginning to buzz. Of course there is a bit of an analogy between Herceptin and DAB389-EGF. Herceptin is a monoclonal antibody directed against HER2 which is really a receptor of an EGF like molecule (HER stands for Human EGF Receptor) and the concept is to kill cells (breast tumors) that over express EGF-related receptors. SRGN's DAB389-EGF is a toxin coupled to EGF and is designed to kill cells over expressing EGF (including breast tumors).